BCL2L1 and cancer: For instance, small molecule inhibitors that selectively block anti-apoptotic proteins, such as Bcl-2 or Bcl-xL, have shown efficacy in preclinical models of cancer and are being evaluated in clinical trials for various malignancies [114, 115].